You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 380 Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
380 Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020348042
Dec 2020112015
Jan 202178016
Feb 202192010
Mar 202194014
Apr 2021170023
May 202153029
Jun 20210017
Jul 2021009
Aug 20210015
Sep 20210013
Oct 202196049
Nov 2021186044
Dec 2021172014
Jan 2022168023
Feb 202281011
Mar 2022168019
Apr 2022170030
May 2022162030
Jun 2022242020
Jul 2022168013
Aug 2022146012
Sep 2022102011
Oct 2022134013
Nov 2022174018
Dec 20226608
Jan 2023120015
Feb 2023140015
Mar 2023166016
Apr 2023152016
May 2023154020
Jun 2023102020
Jul 2023118023
Aug 2023126018
Sep 20238408
Oct 2023166012
Nov 2023140015
Dec 202314006
Jan 20244402
Feb 20248204
Mar 2024128010
Apr 20249408
May 2024128018
Jun 202498011
Jul 202414009
Aug 202410808
Sep 2024146011
Oct 2024166014
Nov 202415408
Dec 2024116014
Jan 202588014
Feb 20253005
Mar 20250010
Apr 2025007
May 2025007
Jun 2025007
Total63120869